Antimycobacterial drugs By Bohlooli S, PhD School of Medicine, Ardabil University of Medical Sciences.

Slides:



Advertisements
Similar presentations
Chemotherapy of Tuberculosis
Advertisements

Side effects of anti-TB medications HREZ
B.Pharm (Hon.), M. Sc. In Pharm (Pharmacology)
TUBERCULOSIS Pulmonary TB.
All the following are antibiotics used for gram –ve bacteria.
Introduction to Clinical Pharmacology Chapter 10 Antitubercular Drugs
ANTIMYCOBACTERIAL AGENTS
ANTI-TUBERCULOSIS DRUGS
 TUBERCULOSIS.  TB is an ancient infectious disease caused by Mycobacterium tuberculosis. It has been known since 1000 B.C., so it not a new disease.
TREATMENT OF T.B. A special problem within the field of chemotherapy. A special problem within the field of chemotherapy.
Pulmonary TB. BY PROF. AZZA ELMedany Dr. Ishfaq Bukhari.
Anti-tuberculous drugs. Mycobacteria Slow-growing bacillusDormant forms in macrophages.
Antimycobacterial drugs Tuberculosis Treatment of mycobacterial infections is complicated due: Limited information regarding antimycobacterial drug actions.
LEPROSY Caused by bacterium Patients are classified into infectious or noninfectious on the basis of the type and duration of disease and effects of therapy.
I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.
Pharmacological Management of Respiratory tract infections.
Non-pharmacologic Elevate the affected area to facilitate gravity drainage of edema and inflammatory substances – Patients with edema may benefit from.
Antibacterial Inhibitors of Cell Wall Synthesis –Very high therapeutic index Low toxicity with high effectiveness β- lactam Drugs –Inhibit peptidoglycan.
Side effects. Side effects: Isoniazid Rash, abnormal liver function, hepatitis, peripheral neuropathy and mild central nervous system (CNS) effects. Hepatitis.
ANTITUBERCULOUS DRUGS by Dr.Mohammed Abd-Almoneim
Chapter 44 Antituberculosis Drugs Department of pharmacology Liu xiaokang( 刘小康) 2010,3.
Sulfonamides, trimethoprim and Quinolones
Pulmonary TB. BY PROF. AZZA EL- MEDANY Department of Pharmacology.
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 89 Antimycobacterial Agents: Drugs for Tuberculosis, Leprosy,
Module 4 Basic Principles of Treatment. “ubo! ubo! ubo!” (cough for 2 weeks or more) Did not take medication medication In Loving Memory of In Loving.
PHL 424 Antimicrobials 5 th Lecture By Abdelkader Ashour, Ph.D. Phone:
ANTI MYCOBACTERIAL DRUGS Dr.Saeed Ahmad Department of Pharmacology King Saud University.
Chemotherapy of Tuberculosis  Medically important mycobacteria  Mycobacterium Tuberculosis  A typical Mycobacterium  Mycobacterium Leprae.
Copyright (c) 2004 Elsevier Inc. All rights reserved. Antimycobacterial Agents: Drugs for Tuberculosis, Leprosy, and Mycobacterium avium Complex Infections.
Chemotherapy of Tuberculosis By Prof. Azza El-Medany.
Side effects. Side effects: Isoniazid Rash, abnormal liver function, hepatitis, peripheral neuropathy and mild central nervous system (CNS) effects. Hepatitis.
Chemotherapy of Tuberculosis  Medically important mycobacteria  Mycobacterium Tuberculosis  A typical Mycobacterium  Mycobacterium Leprae.
Pulmonary TB. BY PROF.  AZZA ELMedany OBJECTIVES  At the end of lecture, the students should:  Discuss the etiology of tuberculosis  Discuss the.
Antitubercular Agents. Tuberculosis, “TB”Tuberculosis, “TB” Caused by Mycobacterium tuberculosisCaused by Mycobacterium tuberculosis Antitubercular agents.
Mycobacterial, Fungal, & Parasitic Infections Medications for Infection ADN 110/cohort 131.
Chemotherapy Of Mycobacterial Infections Dr.Mohamed daood PhD student in Pharmacology.
Presented by:Professor Dr. Imad A-J Thanoon Department of Pharmacology College of Medicine-University of Mosul.
Drugs For Leprosy And Leishmania د. علياء شطناوي
Antimicrobials - Sulfonamides Antimicrobials - Sulfonamides Pharmacology -1 DSX 215 DSX 215 Dr/ Abdulaziz Saeedan Pharmacy College Pharmacy College 1.
ANTIMYCOBACTERIAL DRUGS Prof. Dr. Ece Genç. LEARNING OUTCOMES Identify the characteristic pharmacodynamic and pharmacokinetic properties of izoniazid.
TUBERCULOSIS. Tuberculosis is a chronic granulomatous disease and is one of the world’s most widespread and deadly illness. It is commonly called as Consumption.
Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.
ANTI-TUBERCULOSIS DRUGS. TUBERCULOSIS Difficult to Treat Grow slowly Cell wall impermeable Inside macrophages Develop resistance Caseation & fibrosis.
Antimycobacterial Drugs September Mycobacteria Mycobacteria are intrinsically resistant to most antibiotics. Because they grow slowly compared with.
Anti-TB Agents Dr. Jeff Hobden MIP. Mycobacterium tuberculosis TB is hard to kill with antibiotics TB is hard to kill with antibiotics Slow growth Slow.
Anti-TB Drugs Roy Krishna, Ph.D. FCP..
Chemotherapy of Tuberculosis
ANTITUBERCULOUS DRUGS by Dr.Mohammed Abd-Almoneim
More Antibiotics Tutoring for Pharmacology
Protein Synthesis Inhibitors
DRUGS USED IN TUBERCULOSIS
Antimycobacterial Drugs
Drugs used in tuberculosis
Antimycobacterial drugs
. Antitubercular Drugs.
Miscellaneous Antibiotics
Drugs used in Tuberculosis
Drug Treatment of Tuberculosis
Antituberculous Agents
Other Protein Synthesis Inhibitor
Anti-Tuberculosis Drugs
Respiratory System Drugs
Chloramphenicol as protein synthesis inhibitor
Introduction to Clinical Pharmacology Chapter 10 Antitubercular Drugs
Anti-Tuberculosis Drugs
Antimycobacterial Drugs
Pharmacology 3 Antimycobacterial drugs Lecture 12 By Prof. Dr
Other Protein Synthesis Inhibitor
TUBERCULOSIS Pulmonary TB Drug therapy Dr. Ishfaq Dr. Aliah.
Lecture 5 By Prof. dr. Mohammed Fahmy
Presentation transcript:

Antimycobacterial drugs By Bohlooli S, PhD School of Medicine, Ardabil University of Medical Sciences

Drugs Used in Tuberculosis First Line Agents  Isoniazid (INH)  Rifampine  Pyrazinamide  Ethambutol  Streptomycin Second Line Agents  Amikacin  Aminosalicylic acid  Capreomycin  Ciprofloxacin  Clofazimine  Cycloserine  Ethionamide  Levofloxacin  Rifabutin  Rifapentine

Isoniazid (INH) Most active drug Water soluble Similar to pyridoxine Good penetration to phagocytic cells

Prodrug: activated by KatG (Catalase proxidase) Active form bind to Acyl carrier protein (AcpM),and KasA (beta-ketoacyl carrier protein synthase), covalently Inhibits synthesis of mycolic acid Isoniazid (INH): Mechanism of Action

Mutation or deletion of KatG Overexpression of inh A (encodes acyl carrier protein reducatase) Overexperssion of ahp C, oxidative stress protection Resistance mutants occur in 1 in 10 6 Isoniazid (INH): Basis of Resistance

Isoniazid (INH): Pharmacokinetics Good absorption from GIT Readily distribute to tissues and body fluids Ratio in CFS: 20 to 100% Metabolism by N-acetyltransferase  Rapid acetylator: hepatoxicity  Slow acetylator: neuropathy

Isoniazid (INH): Clinical Use Single agent in latent tuberculosis In combination with second agent in active form Use pyridoxine in conditions predisposing to neuropathy

Isoniazid (INH): Adverse Reactions Allergic reactions  Fever, skin rashes  Drug induced systemic lupus erythematosus Direct toxicity  Hepatitis: loss of appetite, nausea, vomiting, Jaundice, right upper quadrant pain In 1% patients and fatal Depend on age  Neuropathy: higher in slow acetylators  CNS effects: memory loss, psychosis, seizure  Drug interaction: phenytoin

Rifampin Active against:  gram positive and gram negative cocci,  some enteric bacteria  Mycobacteria  Chlamydia Mechanism:  Binds to DNA dependent RNA polymerase Resistance:  Point mutation in rpo B gene  Prevent binding of rifampin to RNA polymerase

Well absorption Enterohepatic cycle Good distribution to body fluids and tissues and phagocytic cells Adequate level in meningeal inflammation Rifampin: Pharmacokinetic

Together with other drugs for prevention of resistance Atypical mycobacterial infections Leprosy Alternative to INH Prophylaxis in H. influemzae type b contacts Staphylococcal infections highly penicillin-resistant strain of pneumococci Rifampin: Clinical use

Rifampin: adverse reactions Orange color urine, sweat, tears, contact lens Rashes, thrombocytopenia, nephritis Hepatitis Light chain proteinuria Flu-like syndrome: fever, chills, myalgias, anemia, thrombocytopenia, acute tubular necrosis Enzyme inducer

Chemical Sructure

Ethambutol Synthetic, water soluble, heat stable compound An inhibitor of arabinosyl transferase and polymerization of arabinoglycan Resistance due to mutations resulting in overexpression of emb gene products and occur rapidly Good absorption from GIT Elimination: 50% unchanged in Urine

Clinical use  In combination with isoniazid or rifampin Adverse reaction  Retrobulbular neurotitis, loss of visual acuity, red green blindness  Hypersensivity reactions Ethambutol

Chemical Structure

Pyrazinamide Relative of nicotinamide Inactive in neutral pH but active in acidic pH Drug taken up by macrophages Converted to pyrazinoic acid by bacterial pyrazinamidase Mechanism is unknown Clinical use: together with insoniazid or rifampin Resistance is fairly readily acquired Adverse reaction: hepatotoxicity, nausea, vomiting, drug fever, hyperuricemia

Streptomycin Resistance is due to point mutation in gene rps L, encoding S12 ribosomal protein or rrs, encoding 16S ribosomal rRNA Active against extracellular form of tubercle bacille Employed when injectable drug is needed

Alternative second-line drugs for tuberculosis In the case of resistance to the drug of first choice In the case of failure of clinical response When expert guidance is available to deal with the toxic effects.